Anavex Life Sciences Corp logo

Anavex Life Sciences Corp Investor Relations Material

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. The company's lead drug candidate is 2-73 that has completed phase II clinical trial for the treatment of Alzheimer's disease. Its programs also includes ANAVEX 3-71, which is in pre-clinical testing for the treatment of amyotrophic lateral sclerosis disease; and ANAVEX 1-41, a pre-clinical stage small molecule compound for the treatment of epilepsy

Latest company events

Q2 20222022-05-10
Q1 20222022-02-09
Q3 20212021-08-12
Q2 20212021-05-13

Ticker symbol

AVXL

Country

United States of America

About the company

https://www.anavex.com/

Investor Relations Page

https://www.anavex.com/investor-material/

Dig deeper into the Anavex Life Sciences Corp fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot